CD30.CAR EBVSTs

CD30-targeted chimeric antigen receptor T cells with EBV-stimulated T cells and constitutive IL7R (C7R) modification · Baylor College of Medicine

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for CD30.CAR EBVSTs, covering 2025-07-20 to 2026-04-13. Get the full timeline:

Most recent: Clinical Trial Update: Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas [Phase 1]